The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...

Dec 23 (Reuters) - The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' (HIK.L), opens new tab generic version of Novo Nordisk's diabetes drug (NOVOb.CO), opens new tab ...

FDA approved Unloxcyt (cosibelimab-ipdl) for advanced or metastatic cSCC ahead of its PDUFA date of Dec. 28. Unloxcyt is the first PD-L1 blocking antibody approved for cSCC, with a recommended ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

MONDAY, Dec. 23, 2024 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight ...

The Food and Drug Administration announced late Friday that it has approved Zepbound to treat obstructive sleep apnea for those who are moderately or severely obese. The drug is to be used in ...

This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to treat patients with prurigo nodularis. The FDA has approved Galderma’s ...

The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first drug treatment for adults with moderate to severe OSA who also have obesity. The FDA said the approval marks ...

The FDA has approved Celltrion’s Stelara biosimilar Steqeyma (CT-P43), for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults with Crohn’s disease and ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.The medicine, part of the class known as GLP-1 ...

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology conditions, including psoriatic arthritis and inflammatory bowel disease.